Cover Image
市場調查報告書

關節黏性補給療法 - 全球市場分析與預測

MediPoint: Viscosupplementation - Global Analysis and Market Forecasts

出版商 GlobalData 商品編碼 339690
出版日期 內容資訊 英文 201 Pages
訂單完成後即時交付
價格
Back to Top
關節黏性補給療法 - 全球市場分析與預測 MediPoint: Viscosupplementation - Global Analysis and Market Forecasts
出版日期: 2015年06月15日 內容資訊: 英文 201 Pages
簡介

骨關節炎(OA)持續成長為一個公共健康的重擔,也是世界各國肌肉骨骼障礙的一個常見原因。過去十年間,在OA症狀管理中使用玻尿酸(HA)補充增加關節內黏性的療法,已經成為一種普遍被用來取代關節置換手術的選項。今後為了因應醫藥費改革的必要性,需要更進一步推廣關節黏性補給療法。只是專家學者仍抱有疑慮的現況下,關節黏性補給療法可能無法獲得保險理賠。此外由於市場競爭非常嚴峻,各企業為了凸顯產品差異而正積極進行開發活動。以地區分類來看,美國及亞洲市場的成長率最為顯著。

本報告針對全球關節黏性補給療法市場進行分析,調查且考察了療法與相關疾病的概要、基本市場構造、已上市/試驗中的主要產品概略、全球及各地區主要國家的市場趨勢與未來預測、主要企業檔案等內容,提供如後。

第1章 目次

第2章 前言

第3章 療法概要

  • 治療範例
    • 物理治療
    • 藥物治療
    • 玻尿酸關節黏性補給療法
    • 外科手術

第4章 產業概要

  • 程序趨勢
    • 概要
    • 美國
    • 歐盟五國
    • 亞洲
    • 南美
  • 進入市場的途徑
  • 醫藥費給付
  • 企業合併與收購(M&A)及主要合夥(共5件)

第5章 市場促進因素、市場機會、障礙

  • 促進因素:OA的盛行率上升
  • 促進因素:OA的複合療法範例
  • 促進因素:關節黏性補給療法推遲了膝關節的完全置換
  • 促進因素:NSAID、類固醇、麻醉藥的副作用
  • 促進因素:向消費者直接販售
  • 市場機會:適應症的增加
  • 市場機會:新世代波尿酸衍生物
  • 市場機會:關節鏡手術後的使用增加
  • 市場機會:自費市場
  • 市場機會:新興國家市場
  • 障礙:不利的給付方案
  • 障礙:價格崩壞
  • 障礙:有成本效益的藥物療法
  • 障礙:PRP注射的人氣上升是否會影響關節黏性補給療法市場?
  • 障礙:新興國家的高成本意識患者

第6章 未滿足需求

  • 缺乏對膝關節OA關節黏性補給療法的一致意見
  • 證明其他關節的關節黏性補給療法臨床效力的證據不足
  • 對基礎科學認知的進展
  • 超音波引導式注射

第7章 競爭評估

  • 主要關節黏性補給療法產品
    • Adant
    • Arthrum
    • Curavisc
    • Durolane
    • Euflexxa
    • Fermathron
    • Gel-One
    • GoOn
    • Hyalgan
    • Hyalubrix 及 HyalOne
    • Jonexa
    • NeoVisc
    • Orthovisc 及 Monovisc
    • Ostenil
    • Recosyn
    • RenehaVis
    • Supartz/ARTZ
    • Suplasyn
    • Suvenyl
    • Synocrom
    • Synolis V-A
    • Synovial
    • Synvisc 及 Synvisc-1
  • 其他關節黏性補給療法產品

第8章 開發中產品

  • 概要
  • Gel-Syn (IBSA Institut Biochimique S.A.)
  • Cingal (Anika Therapeutics)
  • Hydros-TA (Carbylan Therapeutics)
  • Synvisc-1 (Sanofi) 的額外適應症
  • Hymovis (Fidia Farmaceutici S.p.A.)
  • HA-NSAID複合物(Seikagaku Corporation)
  • Supartz/ARTZ(Seikagaku Corporation)的額外適應症
  • Clodronate-HA複合物 (Abiogen Pharma)

第9章 現在及未來主要企業

  • 企業策略趨勢
  • 主要製造商
    • Anika Therapeutics
    • 中外製藥
    • Ferring Pharmaceuticals
    • Fidia Farmaceutici S.p.A.
    • Meda AB
    • Sanofi
    • Seikagaku Corporation
  • 主要行銷夥伴
    • Bioventus
    • DePuy Synthes
    • Zimmer-Biomet

第10章 市場展望

  • 各國市佔率分析
    • 美國市場
    • 歐盟5國市場
    • 亞洲市場
    • 巴西市場
  • 依市場分類
    • 單次注射
    • 3次注射
    • 5次注射
  • 依地域分類
    • 概要
    • 美國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 日本
    • 巴西
    • 中國
    • 印度

第11章 附錄

圖表一覽

目錄
Product Code: GDME0198MAR

Osteoarthritis (OA) constitutes a growing public health burden, and is the most common cause of musculoskeletal disability across the globe. Intra-articular viscosupplementation with hyaluronic acid (HA) has become an increasingly accepted therapeutic alternative to knee replacement surgery in the symptomatic management of OA over the past decade. Going forward, palliative pain treatments are likely to continue to fare well as healthcare reform kicks in and lag times for knee replacement become the norm. Growth of the viscosupplementation market will be highest in the US and the Asia-Pacific (APAC) region, where there is a significant pent-up demand for early intervention in the management of OA.

The increasing prevalence of OA and the lower cost of prescribing viscosupplementation compared with knee replacement surgery have prompted the medical community to take a closer look at this therapy. However, there is a growing concern among physicians that the updated American Academy of Orthopaedic Surgeons (AAOS) and Osteoarthritis Research Society International (OARSI) treatment guidelines for knee OA will result in increased insurance denials for viscosupplementation. Moving forward, industry consolidation and intense competition in the viscosupplementation arena will cause increasing numbers of companies to augment their research efforts to differentiate their products from the lower-end competitors. The motivation to incorporate the favorable properties of different agents into a more effective viscosupplementation product has led to the manipulation and development of next-generation HA formulations consisting of not only HAs, but also pharmaceuticals, such as corticosteroids.

Highlights

Key Questions Answered

  • Future growth in the viscosupplementation market lies in the one-injection segment. What are the current adoption trends in different geographies? How will one-injection segment drive the market revenue growth in the upcoming years?
  • In the US, some commercial insurers have completely excluded viscosupplementation treatment from their coverage. Even when the criteria for coverage have clearly been met by the patient, denials are common. Has this impacted the procedure volume growth in the US viscosupplementation market?
  • Reimbursement is the single greatest barrier to the market growth for viscosupplementation procedures. How does the current payer mix look like in different countries?
  • In recent years, there has been an expansion in the use of intra-articular HA viscosupplementation for treating OA at hips, shoulders, and other small joints. What are the current adoption trends in different regions?
  • Because the most prevalent treatment regimen varies from region to region, the competitive landscape in the viscosupplementation space can be quite different across the geographies covered in this report. Who are the leading players in the viscosupplementation market in different countries?

Reasons to buy

  • "What Do Physicians Think" quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Treatment Modalities Overview

  • 3.1. Treatment Paradigm
    • 3.1.1. Physical Therapies
    • 3.1.2. Medications
    • 3.1.3. Hyaluronic Acid Viscosupplementation
    • 3.1.4. Surgical Intervention

4. Industry Overview

  • 4.1. Procedural Trends
    • 4.1.1. Overview
    • 4.1.2. US
    • 4.1.3. 5EU
    • 4.1.4. Asia-Pacific
    • 4.1.5. South America
  • 4.2. Market Access
    • 4.2.1. US
    • 4.2.2. 5EU
    • 4.2.3. Asia-Pacific
    • 4.2.4. South America
  • 4.3. Reimbursement
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Asia-Pacific
    • 4.3.4. South America
  • 4.4. Mergers and Acquisitions/Key Partnerships
    • 4.4.1. Meda AB Acquires Rottapharm|Medaus for $3.1 Billion (October 2014)
    • 4.4.2. Founders of Anteis Establish Aptissen (March 2014)
    • 4.4.3. Bioventus Acquires Durolane Assets from Galderma (February 2014)
    • 4.4.4. Zimmer to Combine with Biomet in a Transaction Valued at $13.35 Billion (April 2014)
    • 4.4.5. Johnson & Johnson Acquires Synthes for $19.7 Billion (June 2012)

5. Market Drivers, Opportunities, and Barriers

  • 5.1. Driver: Rising Prevalence of OA
  • 5.2. Driver: Multimodal Treatment Paradigm for OA
  • 5.3. Driver: Viscosupplementation Delays Total Knee Replacement
  • 5.4. Driver: Side Effects of NSAIDs, Corticosteroids, and Narcotics
  • 5.5. Driver: Direct-To-Consumer Marketing
  • 5.6. Opportunity: Expanding Indications
  • 5.7. Opportunity: New-Generation HA Derivatives
  • 5.8. Opportunity: Increased Use After Arthroscopic Surgeries
  • 5.9. Opportunity: Self-Pay Market
  • 5.10. Opportunity: Emerging Countries
  • 5.11. Barrier: Unfavorable Reimbursement Scenario
  • 5.12. Barrier: Pricing Erosion
  • 5.13. Barrier: Cost-Effective Pharmacological Therapies
  • 5.14. Barrier: Will The Rising Popularity of PRP Injection Impact the Viscosupplementation Market?
  • 5.15. Barrier: Cost-Conscious Patients in Emerging Countries

6. Unmet Needs

  • 6.1. Lack of Consensus on Clinical Efficacy of Viscosupplementation in Knee OA
  • 6.2. Insufficient Evidence to Prove the Clinical Efficacy of Viscosupplementation in Other Joints
  • 6.3. Better Understanding of the Basic Science
  • 6.4. Ultrasound-Guided Injection

7. Competitive Assessment

  • 7.1. Major Viscosupplementation Products
    • 7.1.1. Adant
    • 7.1.2. Arthrum
    • 7.1.3. Curavisc
    • 7.1.4. Durolane
    • 7.1.5. Euflexxa
    • 7.1.6. Fermathron
    • 7.1.7. Gel-One
    • 7.1.8. Go-On
    • 7.1.9. Hyalgan
    • 7.1.10. Hyalubrix and HyalOne
    • 7.1.11. Jonexa
    • 7.1.12. NeoVisc
    • 7.1.13. Orthovisc and Monovisc
    • 7.1.14. Ostenil
    • 7.1.15. Recosyn
    • 7.1.16. RenehaVis
    • 7.1.17. Supartz/ARTZ
    • 7.1.18. Suplasyn
    • 7.1.19. Suvenyl
    • 7.1.20. Synocrom
    • 7.1.21. Synolis V-A
    • 7.1.22. Synovial
    • 7.1.23. Synvisc and Synvisc-One
  • 7.2. Other Viscosupplementation Products

8. Pipeline Products

  • 8.1. Overview
  • 8.2. Gel-Syn (IBSA Institut Biochimique S.A.)
  • 8.3. Cingal (Anika Therapeutics)
  • 8.4. Hydros-TA (Carbylan Therapeutics)
  • 8.5. Additional Indication for Synvisc-One (Sanofi)
  • 8.6. Hymovis (Fidia Farmaceutici S.p.A.)
  • 8.7. HA-NSAID Conjugates (Seikagaku Corporation)
  • 8.8. Additional Indication for Supartz/ARTZ (Seikagaku Corporation)
  • 8.9. Clodronate-HA Conjugates (Abiogen Pharma)

9. Current and Future Players

  • 9.1. Trends in Corporate Strategy
  • 9.2. Major Manufacturers
    • 9.2.1. Anika Therapeutics
    • 9.2.2. Chugai Pharmaceutical
    • 9.2.3. Ferring Pharmaceuticals
    • 9.2.4. Fidia Farmaceutici S.p.A.
    • 9.2.5. Meda AB
    • 9.2.6. Sanofi
    • 9.2.7. Seikagaku Corporation
  • 9.3. Major Marketing Partners
    • 9.3.1. Bioventus
    • 9.3.2. DePuy Synthes
    • 9.3.3. Zimmer-Biomet

10. Market Outlook

  • 10.1. Market Share Analysis by Country
    • 10.1.1. US Market
    • 10.1.2. 5EU Market
    • 10.1.3. Asia-Pacific Market
    • 10.1.4. Brazil Market
  • 10.2. By Market Segment
    • 10.2.1. One-Injection Segment
    • 10.2.2. Three-Injection Segment
    • 10.2.3. Five-Injection Segment
  • 10.3. By Geography
    • 10.3.1. Overview
    • 10.3.2. US
    • 10.3.3. France
    • 10.3.4. Germany
    • 10.3.5. Italy
    • 10.3.6. Spain
    • 10.3.7. UK
    • 10.3.8. Japan
    • 10.3.9. Brazil
    • 10.3.10. China
    • 10.3.11. India

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Report Methodology
    • 11.3.1. Overview
    • 11.3.2. Coverage
    • 11.3.3. Secondary Research
    • 11.3.4. Forecasting Methodology
    • 11.3.5. Primary Research - Key Opinion Leader Interviews
    • 11.3.6. Expert Panel Validation
  • 11.4. Physicians and Specialists Included in This Study
  • 11.5. About the Authors
    • 11.5.1. Analysts
    • 11.5.2. Jim Coutcher, MS, Global Head of Healthcare
  • 11.6. About MediPoint
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: US Procedure Trends for Viscosupplementation, by Joint Type, 2012-2021
  • Table 2: US Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021
  • Table 3: 5EU Procedure Trends for Viscosupplementation, by Joint Type, 2012-2021
  • Table 4: 5EU Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021
  • Table 5: APAC Procedure Trends for Viscosupplementation, by Joint Type, 2012-2021
  • Table 6: APAC Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021
  • Table 7: Brazil Procedure Trends for Viscosupplementation, by Joint Type, 2012-2021
  • Table 8: Brazil Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021
  • Table 9: Differences Between US FDA Approval and EU CE Marking of Medical Devices
  • Table 10: US Medicare ASPs* for Viscosupplementation Products (2014-2015)
  • Table 11: Potential Clinical Benefits of HA-NSAIDs Conjugates
  • Table 12: Current CPGs on the Use of Viscosupplementation in Joints Other Than the Knee
  • Table 13: Product Profile - Adant
  • Table 14: Product Profile - Arthrum
  • Table 15: Product Profile - Curavisc
  • Table 16: Product Profile - Durolane
  • Table 17: Product Profile - Euflexxa
  • Table 18: Product Profile - Fermathron
  • Table 19: Product Profile - Gel-One
  • Table 20: Product Profile - Go-On
  • Table 21: Product Profile - Hyalgan
  • Table 22: Product Profile - Hyalubrix and HyalOne
  • Table 23: Product Profile - Jonexa
  • Table 24: Product Profile - NeoVisc
  • Table 25: Product Profile - Orthovisc and Monovisc
  • Table 26: Product Profile - Ostenil
  • Table 27: Product Profile - Recosyn
  • Table 28: Product Profile - RenehaVis
  • Table 29: Product Profile - Supartz/ARTZ
  • Table 30: Product Profile - Suplasyn
  • Table 31: Product Profile - Suvenyl
  • Table 32: Product Profile - Synocrom
  • Table 33: Product Profile - Synolis V-A
  • Table 34: Product Profile - Synovial
  • Table 35: Product Profile - Synvisc and Synvisc-One
  • Table 36: Other Viscosupplementation Products in the Global Market, 2015
  • Table 37: Major Pipeline Products in the Viscosupplementation Market, 2015
  • Table 38: Company Profile - Anika Therapeutics
  • Table 39: Anika Therapeutics' Viscosupplementation Portfolio Assessment, 2015
  • Table 40: SWOT Analysis - Anika Therapeutics
  • Table 41: Company Profile - Chugai Pharmaceutical
  • Table 42: Chugai Pharmaceutical's Viscosupplementation Portfolio Assessment, 2015
  • Table 43: SWOT Analysis - Chugai Pharmaceutical
  • Table 44: Company Profile - Ferring Pharmaceuticals
  • Table 45: Ferring Pharmaceutical's Viscosupplementation Portfolio Assessment, 2015
  • Table 46: SWOT Analysis - Ferring Pharmaceuticals
  • Table 47: Company Profile - Fidia Farmaceutici S.p.A.
  • Table 48: Fidia Farmaceutici S.p.A.'s Viscosupplementation Portfolio Assessment, 2015
  • Table 49: SWOT Analysis - Fidia Farmaceutici S.p.A.
  • Table 50: Company Profile - Meda AB
  • Table 51: Meda AB's Viscosupplementation Portfolio Assessment, 2015
  • Table 52: SWOT Analysis - Meda AB
  • Table 53: Company Profile - Sanofi
  • Table 54: Sanofi's Viscosupplementation Portfolio Assessment, 2015
  • Table 55: SWOT Analysis - Sanofi
  • Table 56: Company Profile - Seikagaku Corporation
  • Table 57: Seikagaku Corporation's Viscosupplementation Portfolio Assessment, 2015
  • Table 58: SWOT Analysis - Seikagaku Corporation
  • Table 59: Company Profile - Bioventus
  • Table 60: Bioventus' Viscosupplementation Portfolio Assessment, 2015
  • Table 61: SWOT Analysis - Bioventus
  • Table 62: Company Profile - DePuy Synthes
  • Table 63: DePuy Synthes' Viscosupplementation Portfolio Assessment, 2015
  • Table 64: SWOT Analysis - DePuy Synthes
  • Table 65: Company Profile - Zimmer-Biomet
  • Table 66: Zimmer-Biomet's Viscosupplementation Portfolio Assessment, 2015
  • Table 67: SWOT Analysis - Zimmer-Biomet
  • Table 68: Global Viscosupplementation One-Injection Market Revenue ($m), by Region, 2012-2021
  • Table 69: Global Viscosupplementation Three-Injection Market Revenue ($m), by Region, 2012-2021
  • Table 70: Global Viscosupplementation Five-Injection Market Revenue ($m), by Region, 2012-2021
  • Table 71: Global Viscosupplementation Market Revenue ($m), by Segment, 2011-2020
  • Table 72: Global Viscosupplementation Market Revenue ($m), by Geography, 2012-2021
  • Table 73: US Viscosupplementation Market Revenue ($m), 2012-2021
  • Table 74: France Viscosupplementation Market Revenue ($m), 2012-2021
  • Table 75: Germany Viscosupplementation Market Revenue ($m), 2012-2021
  • Table 76: Italy Viscosupplementation Market Revenue ($m), 2012-2021
  • Table 77: Spain Viscosupplementation Market Revenue ($m), 2012-2021
  • Table 78: UK Viscosupplementation Market Revenue ($m), 2012-2021
  • Table 79: Japan Viscosupplementation Market Revenue ($m), 2012-2021
  • Table 80: Brazil Viscosupplementation Market Revenue ($m), 2012-2021
  • Table 81: China Viscosupplementation Market Revenue ($m), 2012-2021
  • Table 82: India Viscosupplementation Market Revenue ($m), 2012-2021

List of Figures

  • Figure 1: US Physician Adoption Trend for Viscosupplementation, by Specialty
  • Figure 2: US Procedure Trends for Viscosupplementation, by Joint Type, 2014
  • Figure 3: US Adoption Trend for Viscosupplementation, by Treatment Regimen, 2014
  • Figure 4: US Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021
  • Figure 5: 5EU Procedure Trends for Viscosupplementation, by Joint Type, 2014
  • Figure 6: 5EU Adoption Trends for Viscosupplementation, by Treatment Regimen, 2014
  • Figure 7: 5EU Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021
  • Figure 8: APAC Procedure Trends for Viscosupplementation, by Joint Type, 2014
  • Figure 9: APAC Adoption Trend for Viscosupplementation, by Treatment Regimen, 2014
  • Figure 10: APAC Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021
  • Figure 11: Brazil Procedure Trends for Viscosupplementation, by Joint Type, 2014
  • Figure 12: Brazil Adoption Trend for Viscosupplementation, by Treatment Regimen, 2014
  • Figure 13: Brazil Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021
  • Figure 14: US Medicare Reimbursement Trend for Viscosupplementation, 2014-2015*
  • Figure 15: Payer Mix for Viscosupplementation in the US, 2014
  • Figure 16: Payer Mix for Viscosupplementation in France, 2014
  • Figure 17: Payer Mix for Viscosupplementation in Germany, 2014
  • Figure 18: Payer Mix for Viscosupplementation in Italy, 2014
  • Figure 19: Payer Mix for Viscosupplementation in Spain, 2014
  • Figure 20: Payer Mix for Viscosupplementation in the UK, 2014
  • Figure 21: Payer Mix for Viscosupplementation in Japan, 2014
  • Figure 22: Payer Mix for Viscosupplementation in China, 2014
  • Figure 23: Payer Mix for Viscosupplementation in India, 2014
  • Figure 24: Payer Mix for Viscosupplementation in Brazil, 2014
  • Figure 25: US Viscosupplementation Market Share, by Product, 2014
  • Figure 26: France Viscosupplementation Market Share, by Product, 2014
  • Figure 27: Germany Viscosupplementation Market Share, by Product, 2014
  • Figure 28: Italy Viscosupplementation Market Share, by Product, 2014
  • Figure 29: Spain Viscosupplementation Market Share, by Product, 2014
  • Figure 30: UK Viscosupplementation Market Share, by Product, 2014
  • Figure 31: Japan Viscosupplementation Market Share, by Product, 2014
  • Figure 32: China Viscosupplementation Market Share, by Product, 2014
  • Figure 33: India Viscosupplementation Market Share, by Product, 2014
  • Figure 34: Brazil Viscosupplementation Market Share, by Product, 2014
  • Figure 35: Global Viscosupplementation One-Injection Market Revenue ($m), by Region, 2012-2021
  • Figure 36: Global Viscosupplementation Three-Injection Market Revenue ($m), by Region, 2012-2021
  • Figure 37: Global Viscosupplementation Five-Injection Market Revenue ($m), by Region, 2012-2021
  • Figure 38: Global Viscosupplementation Market Revenue ($m), by Segment, 2012-2021
  • Figure 39: Global Viscosupplementation Market Revenue ($m), by Segment, 2014 and 2021
  • Figure 40: Global Viscosupplementation Market Revenue ($m), by Geography, 2014 and 2021
  • Figure 41: US Viscosupplementation Market Revenue ($m), 2012-2021
  • Figure 42: US Viscosupplementation Market Revenue Distribution, 2014 and 2021
  • Figure 43: France Viscosupplementation Market Revenue ($m), 2012-2021
  • Figure 44: France Viscosupplementation Market Revenue Distribution, 2014 and 2021
  • Figure 45: Germany Viscosupplementation Market Revenue ($m), 2012-2021
  • Figure 46: Germany Viscosupplementation Market Revenue Distribution, 2014 and 2021
  • Figure 47: Italy Viscosupplementation Market Revenue ($m), 2012-2021
  • Figure 48: Italy Viscosupplementation Market Revenue Distribution, 2014 and 2021
  • Figure 49: Spain Viscosupplementation Market Revenue ($m), 2012-2021
  • Figure 50: Spain Viscosupplementation Market Revenue Distribution, 2014 and 2021
  • Figure 51: UK Viscosupplementation Market Revenue ($m), 2012-2021
  • Figure 52: UK Viscosupplementation Market Revenue Distribution, 2014 and 2021
  • Figure 53: Japan Viscosupplementation Market Revenue ($m), 2012-2021
  • Figure 54: Japan Viscosupplementation Market Revenue Distribution, 2014 and 2021
  • Figure 55: Brazil Viscosupplementation Market Revenue ($m), 2012-2021
  • Figure 56: Brazil Viscosupplementation Market Revenue Distribution, 2014 and 2021
  • Figure 57: China Viscosupplementation Market Revenue ($m), 2012-2021
  • Figure 58: China Viscosupplementation Market Revenue Distribution, 2014 and 2021
  • Figure 59: India Viscosupplementation Market Revenue ($m), 2012-2021
  • Figure 60: India Viscosupplementation Market Revenue Distribution, 2014 and 2021
  • Figure 61: Breakdown of Physician Survey Participants by Geography (N=61)
  • Figure 62: Breakdown of Other Primary Research Participants by Geography (N=50)
Back to Top